|
業務類別
|
Biotechnology |
|
業務概覽
|
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products. |
| 公司地址
| 121 South Orange Avenue, Suite 1500, Orlando, FL, USA, 32801 |
| 電話號碼
| +1 407 377-6695 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.nutriband.com |
| 員工數量
| 13 |
| Mr. Serguei Melnik |
Chairman of the Board, President and Secretary |
美元 150.00K |
29/04/2026 |
| Dr. Jeff Patrick, Pharm.D. |
Chief Scientific Officer |
-- |
29/04/2026 |
| Dr. Alan Smith, PhD |
Chief Operating Officer and President, 4P Therapeutics |
美元 154.00K |
29/04/2026 |
| Mr. Gerald Goodman |
Chief Financial Officer and Principal Accounting officer |
美元 110.00K |
29/04/2026 |
| Mr. Gareth Sheridan |
Chief Executive Officer and Director |
美元 150.00K |
29/04/2026 |
|
|
| Mr. Sergei Glinka |
Independent Director |
29/04/2026 |
| Mr. Alessandro Puddu |
Independent Director |
29/04/2026 |
| Ms. Viorica Carlig |
Independent Director |
29/04/2026 |
| Mr. Serguei Melnik |
Chairman of the Board, President and Secretary |
29/04/2026 |
| Dr. Stefani C. Mancas, PhD |
Independent Director |
29/04/2026 |
| Ms. Irina Gram |
Independent Director |
29/04/2026 |
| Mr. Mark Hamilton |
Independent Director |
29/04/2026 |
| Mr. Gareth Sheridan |
Chief Executive Officer and Director |
29/04/2026 |
| Mr. Radu Bujoreanu |
Independent Director |
29/04/2026 |
|
|
|
|
